NextCell Pharma AB (OSTO:NXTCL) EV-to-EBITDA : -0.53 (As of May. 23, 2024)

NextCell Pharma AB EV-to-EBITDA Chart

NextCell Pharma AB Annual Data
	Trend	Aug15	Aug16	Aug17	Aug18	Aug19	Aug20	Aug21	Aug22	Aug23
EV-to-EBITDA		Get a 7-Day Free Trial				-4.83	-13.02	-14.90	-3.56	-1.87

NextCell Pharma AB Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EV-to-EBITDA	Get a 7-Day Free Trial															-4.23	-2.56	-1.87	-1.66	-1.58

Competitive Comparison of NextCell Pharma AB's EV-to-EBITDA

For the Biotechnology subindustry, NextCell Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NextCell Pharma AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's EV-to-EBITDA falls into.

NextCell Pharma AB EV-to-EBITDA Calculation

NextCell Pharma AB's EV-to-EBITDA for today is calculated as:

NextCell Pharma AB's current Enterprise Value is kr20.66 Mil.
NextCell Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-38.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB  (OSTO:NXTCL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

NextCell Pharma AB's PE Ratio for today is calculated as:

NextCell Pharma AB's share price for today is kr1.485.
NextCell Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.139.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

NextCell Pharma AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB (OSTO:NXTCL) Business Description